[Form 4] Intensity Therapeutics, Inc. Common stock Insider Trading Activity

Rhea-AI Filing Summary

Ford Motor Company (NYSE: F) has filed a Form 144 indicating that insider Andrew Frick intends to sell up to 30,000 common shares through UBS Financial Services on or about 07-02-2025. The shares were acquired via RSU vesting on 03-04-2024. At the reference price used in the filing, the proposed sale is valued at $345,000, representing roughly 0.0008 % of Ford’s ~3.9 billion shares outstanding. The form also discloses that the same insider sold 30,000 shares on 07-01-2025 for $330,000. No other financial metrics or corporate developments are provided. While the dollar amount is immaterial to Ford’s market capitalization, Form 144 alerts investors to short-term insider selling activity, which some market participants track as a sentiment gauge.

Insights

Corporate Governance Analyst

TL;DR: Small insider sale (30k shares) by Ford VP Andrew Frick; dollar size immaterial, but signals modest insider liquidity move.

The filing shows an executive exercising RSUs and planning to sell the underlying shares. Because the stake is less than 0.001 % of shares outstanding and under $0.4 million in value, it is not material from a governance or ownership-structure standpoint. The sale timing—immediately after a previous 30k share disposition—suggests routine diversification rather than bearish signaling. No 10b5-1 plan date is listed, so the transaction may be discretionary. Overall impact on governance perception is neutral.

Portfolio Manager

TL;DR: Transaction negligible to valuation; monitor only if insider selling broadens across Ford’s leadership team.

From a portfolio perspective, 30,000 shares equates to less than $0.5 million versus Ford’s multi-billion-dollar float, so liquidity and supply dynamics remain unchanged. However, serial sales by the same insider within consecutive days can draw quantitative screens that flag insider sentiment. Unless further senior executives join in, I view this as routine compensation monetization and maintain a neutral stance on F shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wesolowski John M

(Last) (First) (Middle)

C/O INTENSITY THERAPEUTICS, INC.

1 ENTERPRISE DRIVE, SUITE 430

(Street)

SHELTON CT 06484

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
INTENSITY THERAPEUTICS, INC. [ INTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Principal Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $0.0001 Par Value	06/30/2025		A(1)	V	69,745	A	$0.261(2)	76,436	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person is voluntarily reporting the acquisition of shares under the Issuer's 2024 Employee Stock Purchase Plan (ESPP) in a transaction exempt under Rule 16b-3(c) and Rule 16b-3(d).

2. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on June 30, 2025.

Remarks:

	/s/ John M. Wesolowski	07/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.